When Sana announced it ran out of cash to research its cancer drugs, investors ran out of patience.  Investors dumped their shares, causing Sana’s stock price to fall 10%.  Now, Sana’s shareholders are fighting back with a class-action.

In 2023, Sana had three major drug candidates, including two cancer-fighting agents.  Sana told investors it had enough cash on hand to fund research for at least a few years.  It also told investors it was making major strides in its research and started a Phase 1 trial on one of the drugs.

In reality, Sana was bleeding cash.  By late 2023, the Company halted research on one of the drugs, claiming that would help it continue the other two. 

But that wasn’t enough.  In November 2024, Sana dropped a bombshell: it pulled the plug on the other two drugs altogether because it was cash-strapped. 

Angry investors dumped their shares, causing Sana’s stock to plummet.  Now, some of those investors are joining the lawsuit. 

When insurance companies zapped Zynex for massive insurance fraud, its revenues plummeted.  Shocked investors dumped their shares and Zynex’s stock lost fifty-one percent overnight.   Now those investors are fighting back with a class action against Zynex. 

Zynex makes electrotherapy devices for pain management and its revenue depends on insurance reimbursements.  Throughout 2020 to 2024, Zynex touted record profits and sales.  Then, a June 2024 medical journal article revealed many of those sales were fraudulent.  The article discovered Zynex pushed unneeded and unwanted batteries and pads on customers and then billed insurers thousands for the unnecessary parts.  But, insurers fought back and delisted Zynex.

Investors felt the burn in March 2025 after Zynex said government insurer Tricare stopped paying claims and was investigating Zynex.  The Company also said it had a major revenue shortfall because other insurers had stopped paying, too.

Investors quickly dumped their shares and now more investors are joining the lawsuit. 

Ultra Clean Holdings isn’t so squeaky clean after it revealed “unexpected softness” in the Chinese market.  Infuriated investors took Ultra Clean stock to the cleaners after this revelation, sending for it a 28% nosedive.  Now, some investors have filed a class action to recover their losses.

Ultra Clean manufacturers contamination control technologies for precision industries.  Throughout 2024, Ultra Clean boasted about its major growth in China and claimed it was set to double its Chinese revenue.  In fact, it said this growth was going to continue in 2025. 

But the lawsuit says Ultra Clean executives didn’t know what they were talking about.  In February 2025, Ultra Clean retracted those statements and said the Chinese market was experiencing “unexpected softness.”

Financial analysts were shocked by this about-face.  Irate investors quickly dumped their shares, causing Ultra Clean’s stock price to plummet.  Now, some of those investors are joining the lawsuit. 

SoundHound uses artificial intelligence to create artificial voices, but it turns out its assets were artificial, too.  When investors learned SoundHound had to make millions of dollars in accounting adjustments due to major bookkeeping errors, shareholders rapidly dumped their stock.  Some of those investors are fighting back with class action against the Company.

In t2024, SoundHound admitted to material weaknesses in its financial controls but was working to fix the problem.  Nonetheless, the Company bought out two other AI rivals and boasted about how those buyouts were going to bring investors major value.

It turns out those buyouts only brought headaches.

In March 2025, SoundHound admitted it hadn’t fixed the financial control problems.  In fact, those problems affected the accounting for the buyouts.  It turned out both companies were worth far less than originally thought and SoundHound had to redo its accounting books, meaning it had fewer assets than originally thought.

Investors raced for the exits and SoundHound’s stock price tanked.  Now, some investors are joining the lawsuit.

After Actinium revealed the FDA was years away from approving Actinium’s key drug, investors raced for the exits, sending Actinium’s stock price crashing by 60% in one day.  Now investors are taking legal action to recover their losses.

Actinium is a pharma company investigating Iomab-B, a cancer-fighting drug.  In 2016, Actinium launched Sierra, a Phase 3 trial to study Iomab-B’s effectiveness.  Sierra had an unusual study design, but Actinium claimed the FDA not only approved the design but helped come up with it.

In 2022, Actinium claimed Iomab-B was a success and set for FDA approval.

So investors were stunned when, in August 2024, the FDA said not so fast.  The government said Actinium needed to do far more research on Iomab-B and had to use more conventional research methods this time around.

Furious investors dumped their shares and Actinium’s share price crashed.  Now, more investors are joining the lawsuit.

enCore Energy hit rock bottom when it revealed a sixty-three million loss and material weaknesses in its internal controls.  Furious investors ditched their enCore shares, crashing the Company’s stock price crashing by 46%.  Now, investors are fighting back with a class action. 

enCore is a uranium energy company.  Throughout 2024, it filed SEC papers reassuring investors that it maintained proper financial controls.  The Company also filed quarterly updates showing its finances were nearly the same as in 2023.

Behind the scenes, enCore executives knew that was all a lie, according to the Complaint.

Investors learned the bitter truth in March 2025, when enCore announced it suffered a $63 million loss in 2024 – more than double its loss from 2023.  The news got worse – the Company also revealed it had material weaknesses in its internal controls and the company knew about it throughout 2024 but didn’t tell investors. 

Irate investors quickly dumped their shares, sending enCore’s stock price into freefall.  Some of those investors are now joining the lawsuit. 

Investors were left holding fool’s gold after Perpetua Resources increased capital expenses 75%, despite reassurances everything was okay  Perpetua’s stock price caved in after its investors rapidly sold off their shares, sending the Company’s shares plunging by 22%.  Now, furious investors are suing the company to recover their losses. 

Perpetua is revamping an Idaho gold mine – one of the largest in the U.S.   Throughout 2024,  it told investors glittery stories about how expenses were under control or might be increasing just a bit due to inflation.  But Perpetua’s executives knew that story was just a bunch of rocks.

Investors learned the hard truth in February 2025 after Perpetua filed revised financials and revealed its expenses were up a jaw-dropping $952 million– a 75% increase. 

Once investors saw those numbers, they dumped their shares and Perpetua’s stock price tanked.  Now, some of those investors are joining the class action.

Shipping giant TFI crashed out when it revealed its trucking business had been on the decline for a year, but Company executives hid the fact from stockholders.  When they learned the truth, enraged investors dumped their shares, causing TFI’s stock price to plummet 20% in just a day.  Now, those investors are fighting back with a class action.

Throughout 2024, TFI told investors its income was down.  But, TFI’s executives had all sorts of excuses: The Company’s investments weren’t doing as well, the Company wasn’t selling off as much equipment, and, perhaps, the Company wasn’t shipping as much.  But, it turns out, the truth was TFI’s business was declining and it couldn’t control costs.  Just, no one said that to stockholders ... until February 2025. 

In February, the Company released a catastrophic finance report showing income was way down.  TFI couldn’t hide it anymore: the Company’s largest segment was down 15%  over the last year, it was losing small and medium business customers, and its expenses were exploding.

Angry investors rapidly sold off, sending TFI crashing.  Some of those investors are now joining the lawsuit.  

When Geron’s revenue flatlined, investors pulled the plug on their shares, sending the Company’s stock price plummeting 32% overnight.   Now those investors are fighting back with a class-action lawsuit against Geron.

Geron is a pharmaceutical company which developed the drug Rytelo.  In 2024, Geron announced it would be launching Rytelo and was confident it would be a hit.  Soon after, Geron released sales data showing Rytelo was booming.  Executives said Rytelo showed promising future growth and continued demand.

But the lawsuit says that was all a lie.  Geron concealed that Rytelo was inconvenient to take and its marketing was dull.   

Investors learned the truth in February 2025.  Geron executives revealed Rytelo sales stalled out and Geron’s revenue flatlined.  Furious investors quickly sold off Geron shares and the stock price crashed.  Some of those investors are now joining the lawsuit. 

After Fluence Energy slashed its revenue guidance, many investors ditched their shares.  Fluence’s stock price crashed a whopping 47% overnight.  Now, investors are fighting back with a class-action lawsuit against the Company.  

Fluence is a joint venture between Seimens and AED, which are also Fluence’s two biggest customers.  So things got bad for Fluence when Seimens sued Fluence for breach of contract and AED pulled back business. But, Fluence’s executives hid that news from investors – for a while. 

A 2024 shortseller report revealed the bad news and more.  The report not only exposed the lawsuits and business pull back, but also accused Fluence of some dodgy accounting practices used to cover-up what was going on.  Fluence denied the allegations and said everything was fine.

Investors learned the hard truth in February 2025 when Fluence released a catastrophic earnings report.  Revenue was down forty-nine percent and the Company slashed its revenue guidance. 

Irate investors rushed for the exits, causing Fluence’s stock price to plummet.  Some of those investors are joining the lawsuit.  

 Ready Capital’s investors weren’t ready for this bad news like this.  In March, the real estate investment company announced it wrote off hundreds of millions of dollars in bad debt.  Irate investors rushed for the exits, causing RC’s stock price to crash.  Now, those investors are fighting back with a class-action lawsuit. 

In November 2024, Ready Capital announced amazing financial results.  Its CEO bragged about the Company’s strong debt position and the strength of Ready’s commercial real estate portfolio.  The Company also said it regularly checked credit quality when updating the Company’s financials.

Perhaps Ready should have double-checked.   In March 2025, the Company shocked investors when it revealed it had to write off $284 million in bad debt, mostly from commercial real estate.  This move cost investors about $2.50/share.  The Company also said it had to take other “decisive actions” to stabilize its balance sheet. 

Furious investors quickly sold off their shares and RC stock plunged 26.8% overnight. 

Investors didn’t love what they heard when they discovered AppLovin’s new AXON technology was a big fraud.  Furious investors threw their AppLovin shares in the trash, sending the Company’s stock price into freefall.  Now, some of those investors are fighting back and have filed a class-action against the Company.  

In 2023, AppLovin announced AXON 2.0, which it claimed would use “cutting-edge AI technologies” to efficiently match advertisers with mobile games.  A year later, the Company claimed AXON was a success and boasted big revenue gains.  In fact, AppLovin claimed AXON was set to expand into other sectors like e-commerce.   

But the lawsuit says AppLovin’s executives always knew this was a bad romance.     

In February 2025, two research reports revealed AppLovin’s success depended on underhanded tactics that installed apps without users’ permission.  The Company showed these download figures to advertisers, claiming AXON helped generate user downloads.  The reports also said AXON was nothing special – in reality, AppLovin just piggybacked off Meta’s data.     

Once investors saw this news, they dumped AppLovin, and the stock price plunged 12% in just a day.  Some of those investors are now joining the lawsuit.   

There’s no putting lipstick on this one: Elf Beauty faked its financials and shareholders are furious.  After a shortseller report revealed the cosmetics manufacturer lied about inventory levels, investors dumped their shares, causing Elf’s stock price to take a hit.  Now, some of those investors are taking legal action.   

In 2023 to 2024, Elf’s executives posted rosy financials, consistently showing over 70% sales growth.  At the same time, Elf’s CFO admitted the Company’s inventory ballooned but said this was because demand increased.  She said inventory levels were “appropriate.”   

 The lawsuit says that was lie.  

 A November 2024 shortseller report discovered Elf overstated its revenue for at least three quarters.  It also found out Elf hadn’t intended for the inventory build-up and the excess inventory hurt Elf’s bottom line.  So, Elf executives reported fake revenue figures to help smooth out the hit taken from the inventory build-up.   

 Once investors learned the truth, Elf’s stock price dropped.  Some investors are now joining the lawsuit.  

Investors in Maravai Lifesciences felt weak in the knees after the biotech company revealed it discovered “material weaknesses” in its financial controls.  Furious investors quickly ditched their Maravai shares and the stock’s price nosedived.  Some investors are suing the Company to recover their losses. 

In August and November 2024, Maravai posted its quarterly financial results, including its quarterly revenue.   Maravai also reported taking a major goodwill impairment in one of its four divisions.  But, Maravai reassured investors it took a hard look at the other three divisions and no other impairments were needed.  

But that wasn’t true.  In February, Maravai shocked investors when it revealed “material weaknesses” in its financial reporting required it to retract and revise its August and November reports.  The bad news got worse when the Company also said it might have to take a big impairment in another one of its divisions.   

Irate investors dumped their shares and Maravai’s stock price crashed.  Now, some of those investors are joining the class-action lawsuit.   

Quantum Computing suffered a short-circuit after a shocking report revealed the Company’s customers, contracts, and facilities were fake.  Outraged investors pulled the plug on their Quantum shares, sending the Company’s stock into a freefall.  Some of those investors are now taking legal action to recover their losses.  

For years, Quantum bragged about its multi-million dollar contracts with NASA and a few other companies.  It also claimed it was building a massive facility in Phoenix to manufacture its cutting-edge TFLN computing chips.   

But investors got a nasty surprise in December and January.   In December 2024, a shortseller report revealed the Phoenix facility was just a tiny lab incapable of mass production.   

Then in January another report revealed Quantum only ever had one contract with NASA worth $26,000.  Some of Quantum’s contracts with other companies just sham contracts with companies owned by Quantum’s owners. 

Stunned investors dumped their shares, causing Quantum’s stock to plunge 15%.  Some investors are now joining the lawsuit.  

Skyworks Solutions slashed its projections and dashed investors’ hopes after it revealed its semiconductors won’t be used in the iPhone 17.  Stunned investors dumped their Skyworks shares causing the stock to nosedive 24%.  Now, some of those investors are taking legal action to recover their losses.  

In July 2024, Skyworks’ executives told investors it expected its smartphone business to be up 20% and that smartphone AI features would drive this growth.  The Company expected over a billion dollars in quarterly revenues.   

But, those projections were too hasty.  

In February 2025, Skyworks executives stunned investors when they revealed Skyworks’ biggest customer, Apple, pulled the plug on Skyworks because Skyworks’ semiconductors failed to meet benchmarks for the upcoming iPhone 17. Skyworks also revealed revenue was down and that it expected its mobile sector to decline.   

Investors quickly dumped their shares.  Some of those investors are now joining the class-action. 

Rocket Lab USA’s stock price had a crash landing after shocking allegations revealed the Company’s Neutron system wasn’t ready for take-off.  Irate investors saw their stars fizzle out and then dumped their shares, causing Rocket Lab’s stock price plummeting 25% in just a day.  Some investors have filed a class-action to recover their losses.   

In November 2024, Rocket Labs boasted to investors about “significant progress” it made on “Neutron,” a space vehicle launcher designed to be reusable and more cost efficient.  The Company even claimed Neutron was set for a “mid-2025 launch."  Rocket Labs further claimed it already landed a customer and contracted multiple launches using Neutron.   But, the lawsuit says all those claims were hot air.   

Investors learned the truth in February 2025 when Bleecker Street Research published a report showing Rocket Labs wasn't close to launching Neutron in 2025.  In fact, the contract was made at a major discount with an “unreliable start up.”  

Stunned investors quickly sold off their shares, causing Rocket Lab's stock price to freefall.  Now, some of those investors are joining the class-action.   

Manhattan Associates’ left investors speechless when it missed its financial projections and slashed its guidance.  Shocked investors quickly dumped their shares and Manhattan’s stock went into freefall, losing 25% in just a day.  Now, investors are taking legal action.   

In October 2024, Manhattan announced its revenue projections for the coming year.  The Company expressed confidence that demand for Manhattan’s services remained strong despite the shaky economic environment.  In fact, the Company’s CEO called the estimates “responsible.”   

But the guidance proved irresponsible.  In January 2025, Manhattan released terrible financial results and slashed its guidance.  The Company blamed the failure on economic “headwinds,” despite saying it was holding on strong just a few months before. 

Furious investors ditched their shares, sending Manhattan’s stock price tumbling.  Some of those investors are now joining the class-action.  

Investors soured on Constellation Brands after it missed it missed its sales slumped and it missed its financial guidance.   Shareholders “poured out” their shares, causing Constellation’s stock price to plunge 17%.  Some investors have filed a class-action to recover their losses. 

 Constellation Brands produces and sells beer, wine, and spirits in several countries.  Throughout 2023, the spirit and wine industry experienced a slowdown.  But, that didn’t stop Constellation’s executives from giving investors a bubbly outlook for the coming year.   In April 2024, Constellation’s executives provided investors a rosy annual financial outlook, predicting growth in beer, wine, and spirits. 

 But, spirits and wine were still on the rocks. 

 Investors learned the truth in January 2025 after Constellation announced a huge sales miss across all sectors.    Stunned shareholders quickly dumped their shares.  Some investors are now joining the lawsuit.  

Investors and analysts were shocked when the Trade Desk revealed its revenue plummeted after it botched the rollout of its new AI technology.  Furious investors quickly dumped their shares, causing Trade Desk’s stock price to plunge 32%.  Now, investors are taking legal action against the Company.  

The Trade Desk is a digital marketing company that helps marketers plan ad campaigns.  In 2023 it unveiled a new AI-assisted ad technology, “Kokai,” that would help advertisers manage budgets.  Trade Desk executives claimed Kokai would take about a year to launch.  

But Trade Desk botched the roll out.  In February 2025, the Company announced Kokai’s roll-out was taking much longer than expected.  Investors and analysts were stunned when the Company revealed this delay was “intentional.”  The news got worse when Trade Desk revealed revenue had cratered and upcoming revenue was going to be less than expected, too.   

After the news, investors sold their shares and Trade Desk’s stock price plunged.  Some of those investors are now joining the lawsuit.  

After a US Congressman made shocking allegations against TransMedics, its stock price plunged 11%.  Furious shareholders have now filed a class action lawsuit against the Company to recover their losses. 

 TransMedics manufactures devices necessary for cold transporting organs used in transplants.   

 In February 2024, Rep. Paul Gosar sent TransMedics a scathing letter accusing the Company of price-gouging and using coercive sales tactics.  His letter said TransMedics’ extreme prices held the public “hostage” for life-saving technology. 

 Then, in January 2025, short seller Scorpion Capital published a research report confirming all of Gosar’s allegations.  In fact, Scorpion said the situation was much worse, accusing TransMedics of “the most extreme and grotesque healthcare fraud” Scorpion had ever encountered.  

 Angry investors quickly dumped their shares after the Scorpion report.   Some of those investors are now joining the class-action.  

After PVC pipe manufacturer Atkore became the target of an antitrust lawsuit, its stock price sprung a major leak.   Irate investors dumped their shares and the Company’s stock price plunged 20%.  Now, some investors have filed a class-action to plug up their losses.   

 In July 2024, a shortseller report revealed price fixing in the US PVC pipe industry.  The report accused Atkore and other US PVC manufactures of illegally price coordination. In August 2024, Atkore became the target of a civil antitrust lawsuit.  The lawsuit accused the Atkore of using the PVC-price cartel to illegally inflate the Company's profits.  The lawsuit alleges Atkore’s revenue was unsustainable without the illicit cartel scheme. 

In February 2025, Atkore’s profits sprung a leak when the Company announced horrible financial results.  The Company slashed its financial guidance and furious investors rapidly ditched their shares. 

Now, some of those investors are joining the lawsuit. 

Pesticides manufacturer FMC killed investors’ hopes when it missed its revenue guidance because of sales downturn. Furious investors plucked their shares out of FMC, causing the Company’s stock price to fall 33% overnight. Some investors have filed a class-action against FMC to recover their lost “green.”

In late 2023, FMC announced its annual outlook, projecting 3% revenue growth in the coming year. A few months later, FMC also announced “Project Focus,” an effort to cut costs in response to a downturn in Latin America and other areas. Still, FMC executives remained confident in the revenue growth projection.

Investors were shocked when, in February 2025, FMC executives revealed revenue was down 5%. Executives blamed the “unprecedented downturn” on weak demand in Latin America and other areas.

Stunned investors quickly dumped their FMC shares, causing the stock price to tumble. Some investors are now joining the class action.

When ICON revealed a “revenue shortfall” of $100 million and slashed financial projections, investors quickly dumped their shares.  ICON’s stock price plunged 20%, prompting some investors to file a class-action lawsuit to recover their losses. 

ICON is a research organization that assists biotech companies complete clinical trials.  When the pharmaceutical industry got hit with rising costs and high interest rates, those companies dumped ICON to reduce costs.  But ICON executives told investors it was benefitting from these market shifts and said business had “never been better.”   

Investors learned the truth in October 2024 when ICON issued a shocking financial report.  It revealed a $100 million “revenue shortfall” and slashed its annual revenue guidance by $220 million.  Analyst research revealed ICON executives knew about those problems for months beforehand but hid the truth from investors. 

Shocked investors quickly sold off their ICON stock.  Some of those investors are now joining the class-action lawsuit.  

Neumora shocked investors and analysts when it announced its antidepressant navacaprant flopped in clinical trials.  Shocked investors quickly sold off their shares, and Neumora’s stock price tumbled.  Some investors filed a class-action against the Company to recover their losses.  

Neurmora conducted an IPO in September 2023.  At that time, the Company was conducting Phase 2 trials on navacaprant, a investigatory anti-depressant drug.  The lawsuit says the Phase 2 trials had major issues, such as being too small and being poorly designed to control for gender.    

In January 2025, Neumora revealed navacaprant failed the Phase 3 trial.  Analysts were shocked and called the failure a “worst case scenario.”  Analysts noted the severe design issues and said the study failure might have been prevented from the start, if the study had been designed properly.   

Since the IPO, Neumora’s stock price has fallen 88.7%.  Some Neumora investors are now joining the class action lawsuit.   

ModivCare made investors sick when it revealed its cash flow was on life support and the Company had liquidity problems.  After learning this news, investors rapidly dumped their shares and ModivCare’s stock price dropped 10% overnight.  Some of those investors have filed a class-action lawsuit against the Company. 

ModivCare provides medical services including medical transport services.  In 2022, the Company’s CEO revealed ModivCare was renegotiating many of its transport contracts.  But, he reassured investors this was going to be “beneficial.”   He later raised the Company’s revenue guidance when discussing these contracts. 

 But behind the scenes, ModivCare executives knew things were bad.  The Company repeatedly announced negative cash flow and had racked up debt.  By September 2024, the Company announced it was having major liquidity problems.   A couple days later, the ModivCare slashed its guidance.   

 Stunned investors quickly sold off their shares.  Some of those investors are now joining the class-action.   

Investors in GSK got heartburn when they discovered the pharmaceutical giant might be on the hook for billions in a lawsuit about its drug Zantac.  Stunned investors quickly dumped their GSK shares, causing GSK’s price to drop 13% in less than a week.  Some of those investors have filed a class-action to recover their losses.

GSK manufactured Zantac, a best-selling heartburn drug.  But, since at least 1983, GSK knew Zantac could cause cancer, but swept that evidence under the rug.  GSK routinely denied Zantac caused cancer and claimed the drug was safe.

When Zantac users who developed cancer used GSK, the Company denied the allegations and said the science didn’t back it up.  But, in 2022, Credit Suisse estimated GSK was probably liable for up to ten billion dollars.

Investors rapidly sold their shares on this news.  Some of those investors are now joining the lawsuit. 

When Integral Ad Science slashed its ad prices, it ended up slashing its bottom line instead. Now, angry investors have filed a class-action lawsuit against the Company to recover their losses.

Throughout 2023, Integral’s CEO boasted about scoring new contracts with major clients. She said the reason for the Company’s success was customer service and great technology. But, what she didn’t tell investors was that Integral was offering bargain prices it couldn’t sustain.

Investors learned the truth in February 2024 when the Company issued an awful earnings report. Integral revealed it was offering massive discounts to clients to score contracts. Analysts said they were shocked by the revelation.

Stunned quickly dumped their shares, causing Integral’s stock price to tumble 41% overnight. Some of those investors are now joining the lawsuit.

After federal investigators made stunning allegations against pharmacy giant Walgreens Boots Alliance ("Walgreens"), Walgreens’ stock plunged 12% in just a day.  Now, some furious investors have filed a class-action lawsuit against the Company.

For years, Walgreens reported making billions on prescription drug sales.  The Company said it followed controlled substance laws, especially related to opioids.  But, the lawsuit says that was a lie.

In January 2025, the U.S. Department of Justice ("DOJ") filed charges against Walgreens.  The DOJ alleges Walgreens told pharmacists to purposefully violate the Controlled Substances Act.  This alleged conduct helped the Company drive up revenue on the back of wrongful opioid sales.  Some of those prescriptions fraudulently billed Medicare and Medicaid, according to the DOJ.

After learning of the DOJ allegations, investors rapidly dumped their shares.  Some of those investors are now joining the class-action lawsuit.

When Telus International shifted from call centers to AI, its finances took a huge hit. Telus shareholders are now suing the Company to recover their losses.

Tech company Telus International typically provided call center solutions to businesses. But, in 2020 it shifted toward AI, despite the call centers’ proven success.

Throughout 2023, Telus’ CEO boasted about the AI market’s growth potential and said the Company was doing extremely well in AI. At the same time, though, the Company experienced losses which Telus blamed on “macroeconomic pressures.” The Complaint says Telus executives knew that wasn’t true.

Investors learned the truth in August 2024 when the Company announced staggering losses, including a 15% decline in revenue. The CEO admitted these losses were due to the move to AI “cannibalizing” Telus’ traditional call center revenue.

Furious investors quickly dumped their Telus shares, sending the Company’s stock tumbling 36% overnight. Now, some of those investors are joining the lawsuit.

Investors discovered there was something rotten at Grocery Outlet after the discount grocer released a sour finance report.   Once investors got a sniff of the truth – that a tech roll-out gone wrong was costing the Company millions – shareholders quickly tossed out their shares, sending Grocery Outlet’s stock price plummeting 19%.  Now, some of those shareholders have filed a class-action lawsuit to recover their losses. 

In November 2023, Grocery Outlet executives told investors the Company was undergoing a “systems transitions” would hurt financial results for the remainder of the year.  But, Company executives assured investors the disruption would be done by the end of 2023.   

Investors first got a whiff that something was wrong when, in February 2024, the Company announced the transition as taking “longer than anticipated,” so first quarter financial results had also gone bad. 

But investors lost their patience in May 2024 when the Company released a dire financial report in which it admitted the transition continued to hurt finances.  Analysts were stunned and investors quickly sold off their shares. 

Now, some of those investors are joining the lawsuit.   

Advertising firm Cardlytics didn’t seal the deal with investors after it announced revenue and billings were way down.  Angry investors quickly dumped Carlytics stock, causing the Company’s share price to plunge a staggering 57% in one day.  Some of those shareholders are now suing the Company to recover their losses. 

 Cardlytics operates an advertising platform.  It partners with companies to offer consumers discounts and incentives, which are paid out of Cardlytics’ pocket.  In March 2024, the Company issued a glowing financial report and said it was on the path to major revenue growth throughout the year.   

 But that wasn’t the case.   

 The Company’s incentive program cost way too much.  In August 2024 the Company revealed revenues were down 9%t because incentive payments were out of control.  The Company slashed then slashed its financial projections. 

 Stunned investors quickly sold off their shares.  Some of those investors are now joining the lawsuit.    

Pharmaceutical giant Novo Nordisk made investors sick when it revealed a weight loss study went wrong.  Angry investors turned the scales against Novo and tossed out their shares, sending Novo’s share price tumbling over 17% in just one day.  Now, some investors have filed class-action against the Company to recover their losses.  

Novo conducted the REDEFINE study on obesity treatment.  The study looked at Novo’s new drug, CagriSema, in combination with Wegovy. 

The study design said participants would receive a set dose of CagriSema and Wegovy.   

For nearly two years, Novo’s CEO repeatedly said participants would lose at least 25% of their body weight.  But, the lawsuit says he wasn’t being honest. 

In December 2024, Novo published the study results.  Investors were stunned to find out Novo let participants vary their dosage – a big change from the study protocol.  And, participants lost an average of 22.7%t of their body weight.  Analysts called that a huge disappointment and a major difference from the promised 25% weight reduction. 

Stunned investors quickly dumped their shares after learning of the study results. Now, some investors are joining the lawsuit.  

When Essa Pharma announced its key drug, masofaniten, was complete dud, investors pulled the plug on the stock. The sell-off caused Essa’s stock price to plummet a staggering 73% overnight. Shocked shareholders are now taking legal action against the Company.

Essa was investigating masofaniten as a potential prostate cancer treatment. The study combined masofanien with another proven prostate cancer treatment to see if the combo worked even more effectively. In throughout most of 2024, the Company bragged about its Phase 1 study, which the Company claimed was a total success. Essa moved on to a Phase 2 trial about the drug combo.

So investors were stunned in October 2024 when the Company suddenly announced it was not only halting the Phase 2 study, but all studies about masofaniten. The announcement revealed the combination of masofaniten and the proven treatment was actually less effective than the proven treatment alone – meaning masofaniten was a total failure.

The announcement shocked investors and prompted a rapid sell-off of ESSA shares. Now, some of the angry investors are joining the lawsuit.

Investors’ hopes went up in smoke after Innovative Industrial Properties revealed one of its major tenants defaulted on its leases.  The news caused the Company’s stock price to tumble twenty-two percent overnight, prompting some investors to take legal action.

Innovative Industrial Properties leases real estate to government-licensed cannabis companies.   Throughout 2024, Innovative boasted it was going to see a lot of “green” from new leases, especially from its top client PharmaCann.   For three consecutive quarters, the Company's executives boasted about the Company's strong earnings and in particular stated it saw "strong value" in PharmaCann after penning four new leases with the company. 

But, the lawsuit alleges Innovative's executives knew that things were ready to go up in smoke.

Investors were stunned in December 2024 when Innovative revealed PharmaCann defaulted on all eleven of its leases, costing Innovative millions of dollars.

Shocked investors quickly sold their shares, plummeting Innovative’s stock price.

Now, some of those investors signing up for the lawsuit.

State and federal authorities made explosive AML and fraud allegations against Block, the owner of Cash App.  Block paid out $255 million dollars in fines, shocking investors.  Some of those stunned investors are now suing the Company.

Cash App – a popular banking app – was the target of a shocking short-seller investigation in February 2023.  The report alleged Cash App failed to follow anti-money laundering ("AML") laws and turned its eye toward illegal activities done on the platform.  The report further alleged Block's executives knew of these problems but failed to do anything about it.

Forty-eight state attorneys general teamed up after the report to investigate the allegations.  In January 2025, they announced a settlement with Cash App, requiring it to pay a $80 million penalty.

But that wasn’t the end of Cash App’s problems.  The next day, the federal Consumer Financial Protection Bureau ("CFPB") slapped a staggering $180 million penalty on Cash App for putting users at risk of fraud and failing to adequately protect users' information.

Since the shortseller report was published, Block's stock has suffered repeated losses.  Investors are now suing the Company to recover their investment.

A Department of Justice investigation into pharmaceutical manufacturer Regeneron left investors wide-eyed. The stunning allegations caused investors to rapidly sell off their shares and Regeneron’s stock price plunged over nine percent. Some of those investors are now joining a class-action lawsuit against the Company.

Regeneron’s leading products are Eylea and Eylea HD, drugs which treat macular degeneration. In the Company’s February 2024 quarterly financial report, Regeneron reported making $1.4 billion on the Eylea brand. Some of this money came from billing Medicaid and Medicare for Eylea prescriptions.

But, the lawsuit alleges Regeneron’s executives knew the Eylea sales figures were based on fraudulent Medicaid and Medicare billing practices.

In April 2024, the U.S Department of Justice filed a case against the Company alleging Regeneron regularly overbilled the Government for Regeneron prescriptions.

In October, investors learned how much overbilling propped up Regeneron’s bottom line. Quarterly sales for Eylea were $30 million below expectations, due to what the Company called a “lower net selling price.”

Investors quickly dumped their shares after learning this news. Some of those investors are now joining the lawsuit.

Micron Technology’s financial projections short-circuited after it slashed financial projections for 2025.  Investors were stunned, since Micron previously guided to a profitable year.    Shareholders rapidly sold off their stock, causing Micron’s stock price plunging 16%.  Some of those shareholders are taking legal action to recover their losses.

The microchip and computer memory industry suffered weak demand through 2022 and 2023.  But throughout 2024, Micron claimed it made a comeback, especially in its NAND sector.  The Company said it was in a position to “deliver a substantial revenue record” in 2025.

But in December 2024, the Company shocked analysts and investors by claiming its NAND sector suffered a major slowdown.  It also slashed its 2025 guidance.  Analysts responded negatively, cutting their targets for Micron and downgrading their ratings of the stock.  

Investors quickly dumped their shares, causing Micron’s stock to plummet.  Some of those investors are now joining the lawsuit.

Investors’ hopes went dim after solar power company Nextracker revealed its business was slowing down.  This slowdown stunned investors because Nextracker executives had been adamant the business was doing great.  Shocked shareholders dumped their stock, sending share prices tumbling 15%.  Now, some of those investors are taking legal action against the Company.   

Throughout 2024, the solar power industry experienced delays and slowdowns for various reasons. Nonetheless, Nextracker was adamant its business wasn’t slowing down and consistently reported record revenues and profits. The lawsuit alleges Nexttracker executives knew those claims weren’t true. 

 In October 2024, the Company shocked investors and analysts when it admitted it was experiencing the same slowdowns as the rest of the industry.  After Nextracker reported decreased revenues and profits, shareholders raced for the exit.  The news sent Nextracker’s stock price down 15%. 

Some of those angry investors are now joining the lawsuit. 

When BioAge labs announced it was pulling the plug on clinical trials of one of its drugs, investors then pulled the plug on BioAge Labs.  Shareholders quickly dumped their shares and BioAge’s stock price plunged 25% overnight.  Some of those investors are now taking legal action against the Company.

BioAge was investigating a potential obesity treatment called azelaprag.  It had completed Phase 1 trials.  The Phase 2 trial, called STRIDE, was set to complete in late 2025.  BioAge went public in September 2024.  In its IPO papers, BioAge touted azelaprag, the success of the Phase 1 trials, and the ongoing STRIDE trials. 

So investors were shocked in December 2024 when BioAge suddenly halted the STRIDE trial.  The Company revealed some STRIDE participants were showed signs of liver toxicity.  Analysts expressed surprise at the news, noting it is unusual that that liver toxicity had never appeared across any of the eight Phase 1 trials or other investigations BioAge conducted on the drug.

Investors rapidly sold off their shares and BioAge’s stock price plummeted.  Now, some of those investors are joining the lawsuit.

Investors in Revance were stunned after a merger deal took a bad turn, which analysts said caused Revance "reputational damage." The news sent the stock into a free fall, losing 20% in one day.  Furious investors are taking legal action to recover their losses.

In 2020, Biotech company Revance penned a distribution agreement with Teoxane.  The agreement required Revance maintain set purchasing and distribution levels for some of Teoxane’s products. 

In August 2024, Revance announced Crown Labs sought to buy out Revance for $6.66 per share.  Revance’s board agreed to the deal. But in September 2024, Revance announced it received a notice from Teoxane alleging Revance breached the distribution agreement.  Considering that allegation, Crown and Revance put their deal on hold.

Then, in December 2024, Revance announced it finalized the deal with Crown – but Crown slashed its offer by over 50%, to only $3.10 per share. Analysts were stunned by the move and called it a “significant devaluation.”

Investors quickly dumped their stock, causing Revance’s stock price to plunge.  Now, some of those investors are joining the lawsuit.

Investors in Caribou Biosciences were shocked after an analyst report revealed the pharmaceutical firm’s new drug posed safety concerns.  When investors realized they’d been sold snake water, they quickly sold their shares, sending Caribou’s stock price tumbling 25%.  Now, some of those investors are taking legal action to recover their losses.

Caribou Biosciences was researching a new drug called CB 010, which might treat Hodgkin Lymphoma.  In its financial reports, Caribou repeatedly claimed CB 010 showed promising results.  Company executives also claimed Caribou was in great financial shape, with enough cash to last until at least 2026.  But, Caribou executives knew better.

Investors learned the truth in June 2024 when Evercore published a report questioning CB-010’s effectiveness and calling the drug a “safety risk.”  In July 2024, Caribou blindsided investors when it admitted it was running out of cash and had to seriously curtail research activities.

Shocked investors quickly dumped their shares.  Some of those investors are now suing the company.  

Transocean’s stock price sank after it sold two of its rigs for a $630 million loss.   Now, stunned investors are suing the Company to recover some of their damages. 

Transocean provides offshore drilling for oil and gas.  Two of its rigs sat idle since mid-2023.  But, Transocean consistently assured investors that the value of its property and equipment remained stable.  Transocean also told investors it based the valuation on “fair market value.”   

In August 2024, a financial analysts asked Transocean’s CEO about the idle rigs.  The CEO said the rigs remained “strategic assets” and the Company was just looking for the right project.  That wasn’t true.  

In September 2024 the Company sold both rigs, calling them “non-strategic assets.”  The Company recorded a $630 million impairment on the sale, suggesting the rigs had been severely overvalued all along.

Shocked investors rapidly sold off their shares, causing Transocean’s stock price crashing 9% in less than a day.  Now, some of those stunned investors are taking legal action. 

Shocked investors quickly dumped their shares of AstraZeneca after Chinese authorities accused the pharmaceutical giant of insurance fraud.  The sell-off caused AstraZeneca’s stock price to plummet more than 10%, prompting some angry shareholders to file a class-action lawsuit against the Company.

In October 2024, AstraZeneca posted an announcement to its Website stating its Chinese branch president was under investigation by Chinese authorities.  A few days later, a Chinese financial news outlet reported AstraZeneca was being investigated for massive insurance fraud.  Allegedly, the Company forged prescriptions and genetic tests to ramp up benefits for some of its drugs.

In December 2024, the Financial Times published an article stating AstraZeneca executives reported revenue hits in the wake of the arrests and that some Chinese doctors were now reluctant to prescribe AstraZeneca products. 

The articles prompted shocked investors to rapidly sell off their shares.  Some of those investors are now joining the lawsuit. 

Join the Lawsuit.

Investors in Capri Holdings were left with an empty bag when the FTC blocked a proposed merger with Tapestry. Angry investors quickly sold their shares, sending Capri’s stock price into freefall. Some of those shareholders are now suing the Company to recover their losses.

In 2023, fashion company Capri received a merger offer from a rival fashion firm, Tapestry. Shareholders approved the deal. Executives from both companies assured investors they thought regulators would approve the merger.

But soon after FTC announced an anti-trust investigation, believing the proposed merged company would control too much of the handbag market. Both companies repeatedly assured investors the FTC investigation had no merit. But documents uncovered by the FTC revealed otherwise: the Companies knew their merger had major antitrust issues.

So investors were stunned in September 2024 when a federal court sided with the FTC and blocked the merger. The stock price lost 50% overnight.

Some of those shareholders now are joining a lawsuit against Capri.

Join the Lawsuit.

MGP Ingredients gave investors a headache after the distiller admitted it hadn’t been truthful about its inventory levels.   When investors learned the Company had higher inventory levels than indicated, investors quickly dumped their shares, causing MGPI’s stock price to plummet 50%.  Now, some of those investors are signing up for a class action lawsuit to recover their losses.

From 2020 to 2022, alcohol sales spiked during the Covid pandemic.  But, in  2023, when the pandemic waned, people started to drink less, leaving many distillers with excess inventory.  At that time, MGPI executives assured investors that its inventory levels were stable and sales were strong.  Yet, its executives knew better and MGPI warehouses were full of unwanted bottles.

Investors learned the truth in October 2024, when Company executives admitted soft demand for its products and higher inventory levels than previously admitted.

Analysts called the admission “breathtaking” and scolded the company for being deceptive.  Shareholders quickly sold off their stock, causing massive declines.  Now, some of those investors are pursuing legal action against the Company.

Join the Lawsuit.

Investors in Kaspi.Kz (Kaspi) were stunned after a shortseller report made shocking allegations, including violations of international economic sanctions. Stunned investors quickly dropped their shares, sending Kaspi’s stock price down 16%. Now, some of those angry investors are suing the company to recover their losses.

Kaspi is a Kazakhstan-based finance company. In 2024, it made its Initial Public Offering on the NASDAQ.  On its IPO paperwork, Kaspi assured investors it complied with international economic and trade sanctions, and other economic regulations. It also assured investors it properly disclosed any related-party transactions.

But, according to the lawsuit, Kaspi’s executives knew those assurances were far from the truth.

In September 2024, shortseller Culper Research released an explosive report alleging Kaspi knowingly dodged international economic sanctions against Russia. Kaspi also allegedly failed to disclose millions of dollars in related-party transactions with various companies.

Investors quickly sold off their stock after this news, sending Kaspi’s stock price sharply down. Now, some of those investors are signing up for the lawsuit.

Join the Lawsuit.

Investors in Marqueta were stunned when the fintech company announced its profits and revenue were far less than it led investors to expect.  When angry investors rapidly sold off their Marqueta stock, the Company’s stock price dropped over 42% in a day.  Some of those investors are now suing the Company to recover their losses.

Marqueta provides cloud-based platforms to the financial services industry.  In May and August the Company’s executives told investors to expect profit growth of over twenty percent and revenue growth between sixteen and eighteen percent.  But Marqueta’s executives should have known better, as investors would soon find out.

In November, Marqueta issued an earnings report showing profits and revenues far less than they’d led investors to expect. Marqueta’s exectuves said they “anticipated this” due to regulatory changes in banking that occurred last year.  But this explanation left investors asking why Marqueta didn’t anticipate these changes when it issued the sky-high projections just a few months earlier.

Stunned investors quickly sold off their shares, sending Marqueta’s stock price plummeting. Some of those investors are now joining the lawsuit.

Join the Lawsuit.

Applied Therapeutics is under fire after the FDA issued the pharmaceutical company a warning letter for submitting problematic data.  Shocked investors rapidly dumped their shares, causing the Company’s stock price to plummet.  Some of those investors are now suing the Company to recoup their losses.

Applied Therapeutics was investigating govorestat, a drug to treat a glucose disorder.  The Company’s executives made glowing remarks about the likelihood of FDA and European approval. 

But, those executives should have known better.

Investors learned the truth in November 2024 when the FDA issued a Complete Response Letter knocking back the drug citing “deficiencies in the application.”  Then, a few days later, the FDA sent Applied Therapeutics a stern warning letter, revealing inconsistencies in the study’s data.

Investors and analysts were stunned by the revelation, causing the stock’s price to freefall.  Now, some of those investors are joining the lawsuit.

Join the Lawsuit.

After investors learned that Cassava Sciences had lied about its clinical trials, they quickly sold off their shares in the pharmaceutical company, sending its stock price crashing 84%.  Now, some of those furious investors are suing the company to recover their losses. 

Cassava developed simufilam, a potential Alzheimer treatment.  In February 2024, Cassava announced a “clearly desirable clinical outcome” for the drug’s Phase Two clinical trials.  The good news kept coming, as in July the Company announced simufilam had entered an open-label extension study, which is typically a good sign in pharmaceutical studies.  

Things got murky for the Company in June 2024, when it announced that one of its science advisors had been indicted for defrauding the National Institutes of Health. Allegedly, that advisor lied to the NIH on simulfilam’s grant applications. Then, in October, Cassava announced the SEC levied a $40 million fine because Cassava lied about simufilam’s Phase 2b clinical trials.  The Phase 2b trials failed to meet statistical significance, but the Company never told investors about that failure.   

Investors learned the full truth about Simufilam in November, when the Company announced results of the Phase Three trials.   The drug failed all of the Phase Three trials and the Company pulled all further studies.  Investors rapidly sold off their shares after that news, sending Cassava’s stock plummeting.  Now, some of those investors are signing up for the lawsuit.  

When Five9, Inc. issued sky-high financial projections, investors’ hopes were in the clouds.  After the Company’s executives slashed those projections just months later, investors dumped their shares, sending Five9’s stock price crashing and triggered a lawsuit by shareholders seeking to recover their losses.

Five9 provides software for cloud-based business centers.  In June 2024, the Company’s executives said the Company was on track for 16% revenue growth, regardless of the economic environment.  The Company’s CEO said he was certain the Company was on track for an especially strong back half of the year. According to the lawsuit, however, Five9’s executives knew better because the Company was in the midst of a slowdown. In August, the Company released its quarterly financials and slashed its projections due to “uncertain economic conditions”  and stated that the back half of the year looked to be challenging.

Stunned investors quickly sold off their shares, sending Five9’s stock price tumbling.  Now, some of those investors are joining the lawsuit.

Join the Lawsuit.

Investors now doubt the integrity of Sun Communities, Inc. after a recent short-seller report made stunning allegations against the Company’s CEO.  Shocked investors have now filed a class action lawsuit against the company.

According to the lawsuit, in 2019, Sun Communities’ CEO took a $4 million mortgage from the parents of one of the company’s board members.  Under SEC rules, this was a “related-party transaction” that had to be reported, but the Company never filed that paperwork. The truth started to emerge in February when the Company announced that it had discovered major weaknesses in its internal controls and financial reporting. Investors learned the full scope of the problem in September after short-seller Blue Orca published a report detailing the mortgage transaction.  Blue Orca also discovered that the CEO had taken out other personal loans from Sun Communities board members, but none had been reported to the SEC. Shocked investors quickly sold off their shares.  Now, some of those investors are joining the lawsuit.

Join the Lawsuit.

Investors in Customers Bancorp were recently stunned when the Federal Reserve targeted the bank with a major enforcement action.  After learning that the Fed had slammed Customers Bancorp for failing to follow federal anti-money laundering laws, investors quickly dumped their Bancorp shares and the stock lost 15% of its value in a day.  Now, some of those investors are suing Bancorp to recover their losses.

In April 2024, Bancorp abruptly fired its Chief Financial Officer “for cause” but provided no other details.  Then, in August, investors learned the truth: Bancorp had major problems complying with anti-money laundering laws and the Bank Secrecy Act.  The Federal Reserve issued a press release announcing that it had targeted Bancorp with an enforcement action and demanded the bank implement a new risk management plan within sixty days. Investors quickly sold off Bancorp shares as the stock plummeted.  Now, some of those angry investors are signing up for the class action lawsuit. 

Join the Lawsuit.

Investors were left aching when Dentsply recently announced that its orthodontic aligner brand, Byte, had caused some patients major injuries.  Investors quickly sold their shares, dropping Dentsply’s stock price by 28% overnight.  Now, some of those sore investors have filed a class action lawsuit against Dentsply to make up for the pain caused.

In 2023, dental device manufacturer Dentsply acquired Byte, a brand of direct-to-consumer invisible aligners. Byte promised its products were doctor-directed, and Dentsply executives talked up the acquisition, especially Byte’s ability to sell new customers on clear aligners.

However, according to the lawsuit, in October 2024, the company revealed that it was in discussions with the FDA because Byte had purposefully targeted low-income consumers who should not have worn dental aligners.  These patients were treated anyway and sustained major dental injuries.

In November 2024, Dentsply released its quarterly financials, including an almost $500 million write-down on Byte’s value. Investors quickly dumped their shares.  Now, some of those investors are looking to bite back and join the class action lawsuit. 

Join the Lawsuit.

Celsius Holdings, Inc. gave investors the wrong sort of buzz after executives revealed sales were down over $100 million.  Stunned investors emptied out their shares, causing Celsius’ stock price to plummet almost 12%.  Angry investors are now suing the company to recover their losses.

Celsius, a popular energy drink brand, formed a distribution alliance with Pepsi 2022.  The company then reported record sales in 2023, causing its stock price to skyrocket.  Celsius’ executives then cashed out, banking well over $1 billion, but didn’t tell investors that the record sales were because Pepsi had hoarded over two years’ worth of Celsius in warehouses.  Thus, 2023 sales weren’t likely to repeat any time soon.

The truth emerged in September 2024, when a Celsius executive spoke at an industry conference.  He said sales were down almost $100 million because Pepsi was using its massive stockpile to stock shelves instead of ordering new cans.

Stunned investors quickly dumped their shares, causing Celsius’ stock price to crash.  Some of those investors are now signing up for the lawsuit. 

Join the Lawsuit.

When entertainment giant Warner Bros. Discovery, Inc. recently announced that it had taken a $10 billion, investors weren’t amused.  Shareholders quickly dumped their stock, causing Warner Bros.' stock price to tumble 9% overnight.  Some of those shareholders have now filed a lawsuit against the company. 

In February, Warner Bros. announced that it was renegotiating its contract with the NBA, which was a centerpiece of the company’s entertainment line-up, but those negotiations ran long. In August, the company issued its financial results, and investors were shocked when the company announced a $10 billion write-down for the value of the company’s brands and networks. 

According to the lawsuit, Warner Bros.' executives should have known that lengthy negotiations would hurt the brand’s value.  Plaintiff also claims that Warner Bros. executives should have known the brand was overvalued in the first place, which would result in the hefty write-down.  Nonetheless, Warner Bros. executives let investors buy WBD stock at an inflated price.

Now, some of those angry investors are joining the lawsuit.

Join the Lawsuit.

Investors in Zeta Global Holdings quickly dumped their shares after a recent short seller report made shocking allegations against the digital marketing company.  After Zeta’s stock price plummeted 37% overnight, some of Zeta’s investors filed a class action lawsuit to recover their losses.

Zeta is a digital marketing company that holds data about over 240 million Americans.  Zeta says those people voluntarily disclosed their information, but in November Culper Research published a report that raised serious questions about Zeta’s data set.  The Culper report said Zeta tricked consumers into disclosing personal information by setting up bogus web sites like fake job boards.  Culper also claimed Zeta used underhanded tactics to inflate its revenue by over 50%.

Shocked investors quickly sold off their shares after the Culper Report was released.  Now,  some of those investors are signing up for the lawsuit.

Join the Lawsuit.

Aehr Test Systems, Inc. short-circuited investors’ hopes when the semiconductor Company recently slashed its financial projections by millions.  Upset investors quickly sold off their Aehr shares, and Aehr’s stock price fell over 22%.  Now, shareholders have filed a class action lawsuit against the Company.

In late 2023, Aehr issued its 2024 fiscal guidance.  Aehr executives expected at least $100 million in revenue.  In January 2024, Aehr revised projections down to $75-85 million, but the Company’s CEO assured investors there was “no way” the Company would miss this new goal. He was wrong., and in March, the Company stunned investors when it reported dismal quarterly income and slashed its revenue target yet again. After the March revision, investors quickly sold off Aehr’s stock, sending the stock price plummeting.

Join the Lawsuit.

Dutch semiconductor manufacturer ASML Holding N.V. missed the mark when it assured investors that it was on track for record sales by 2025.  So, when investors learned sales had short-circuited and ASML’s projections were off-track, they quickly sold off their stock, causing ASML’s stock price to plummet.  Now, some of those shareholders have filed a class-action lawsuit against the company.

In early 2024, ASML announced record sales, and company executives told investors they expected 30 to 40 billion Euros in sales in 2025.  According to the recent lawsuit, however, executives should have known these projections were far-fetched because the Dutch government imposed strict export regulations on China in 2023. Much of ASML’s sales depended on China, so ASML’s executives should have known hitting their sales goal was almost impossible. In October 2024, investors learned the truth when ASML announced a 53% decline in quarterly bookings.  The Company also slashed its 2025 sales target. 

Investors quickly sold off their ASML stock.  Now, some of those investors are joining the class action lawsuit to recover their losses.

Join the Lawsuit.

In July, the NASDAQ delisted Chinese AI company Xiao-I because it had become a junk stock. Now, angry shareholders are suing the tech company to recover some of their lost investment.

When Xiao-I launched its initial public offering in 2023, its executives should have known the company had problems. It wasn’t in compliance with Chinese foreign investment laws, it didn’t meet NASDAQ accounting requirements, and its AI model needed a lot more work. Xiao-I didn’t tell investors about any of those issues, and investors were outraged when they learned the truth the hard way- when NASDAQ took the shares off the market for failing to meet even minimum quality requirements.

Some of those shareholders are now signing up for the class-action lawsuit.

Join the Lawsuit.